BOURLA ALBERT 4

What Happened
Albert Bourla, Chairman & CEO (and Director) of Pfizer Inc., was granted 23 units treated as phantom shares on 2026-06-15 at a reported per‑unit value of $26.00, for a total value of $598. This was an award/grant (derivative units), not an open‑market purchase of common stock.

Key Details

• Transaction date: 2026-06-15; Form 4 filed 2026-06-16 (appears timely).
• Type: Award/Grant (derivative units) — reported as "A" (acquisition).
• Quantity and value: 23 units × $26.00 = $598.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 — each unit represents one phantom share of common stock. F2 — units were granted under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan; they are settled in cash following separation from service and may be moved into an alternative investment account at any time.
• No 10b5-1 plan or tax‑withholding details are noted in the provided excerpt.

Context
These phantom share units are a form of deferred compensation tied to Pfizer’s stock value and are cash‑settled after the executive’s separation from service. Such awards are routine elements of executive pay and do not represent an immediate purchase of shares on the open market, so they provide limited direct signal about the insider’s view of near‑term stock prospects.